A Post-marketing, Observational, Descriptive Study to Assess the Risk Associated With Pregnancy, the Maternal Complications, and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Omaveloxolone During Pregnancy and/or Lactation

In this study, researchers will learn more about the safety of BIIB141, also known as omaveloxolone or SKYCLARYS. This is a drug available for doctors to prescribe for people with Friedrich's Ataxia, also known as FA. This is known as an "observational" study, which collects health information about study participants without changing their medical care. Participants for this study will have taken BIIB141 at any time during pregnancy and/or while breastfeeding or pumping up through the first year after delivery. Participants can join this study on their own or they may be enrolled by their regular doctors. This study is also known as the "SKYCLARYS (Omaveloxolone) Pregnancy and Lactation Surveillance Program."
The main objective of this study is to learn more about how BIIB141 may affect pregnancy, as well as any effects on the health of the mother and of the baby during its first year of life.
The main question researchers want to answer in this study is:
· Does taking BIIB141 during pregnancy or breastfeeding lead to any major birth defects?
Researchers will also learn more about:
* Does taking BIIB141 during pregnancy or breastfeeding lead to any minor birth defects?
* Does taking BIIB141 during pregnancy or breastfeeding affect the following:
* Gestational diabetes, a disease that can happen during pregnancy that affects how your body uses sugar
* Pre-eclampsia, a pregnancy-related high blood pressure disease
* Unborn baby being small for its expected age (usually in weeks)
* Loss of an unborn baby
* Live birth
* Premature birth
* Loss of a newborn
* Growth or developmental delays in the baby
* Serious illness in the baby resulting in hospitalization
* Serious infections in the baby, or ones in babies with a weakened immune system
This study will be done as follows:
* Participants will join the study after signing an informed consent form, also known as an ICF.
* During the study, health information from the participants' regular visits to their doctor will be collected based on whether participant joined the study while pregnant or after the baby is born.
* Each participant will be in the study for up to 1 year after the birth of their child, unless they decide to leave early. Overall, this study is expected to last at least 10 years.

开始日期2026-10-26

申办/合作机构

Biogen, Inc.

NCT07149415

/ Recruiting临床1期

A Phase 1, Open-Label, Single-Sequence, 2-Period, Drug-Drug Interaction Study in Healthy Participants Evaluating the Effect of Omaveloxolone on the Pharmacokinetics of CYP2C19 Substrate, Omeprazole

In this study, researchers will learn more about BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedrich's Ataxia (FA) who are at least 16 years old. This is called a "drug-drug interaction" study. In this kind of study, researchers are looking at what happens when 2 or more medicines affect each other in the body. This could change how 1 or both of the drugs work, either making them stronger, weaker, or causing health problems.
The main goal of this study is to learn if taking BIIB141 affects how omeprazole is processed in the body. Omeprazole is a commonly used medicine to help lower the amount of acid the stomach makes.
The main question researchers want to answer in this study is :
• How does the body process omeprazole when taken with BIIB141?
Researchers will also learn more about :
* How many participants have adverse events during the study. An adverse event is a health problem that may or may not be caused by the study drug.
* How many participants have adverse reactions during the study. An adverse reaction is a health problem that may be caused by the study drug.
* If there are any changes in the participants' overall health during the study.
This study will be done as follows:
* Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which participants will check into their study research center.
* Participants will stay at the study research center for about 17 days.
* This is an "open label" study. In this kind of study, the participants, study doctor, and site staff know which study drug the participant is taking. In this study, all participants took BIIB141 and omprezole.
* Participants will take omeprazole on Day 1 and Day 16. They will also take BIIB141 once a day from Day 2 through Day 16.
* Throughout the study, researchers will take participants' blood and urine samples. Researchers will also do other tests to check the participants' overall health and will ask participants how they are feeling.
* Each participant will be in the study for up to 45 days.

开始日期2025-09-02

申办/合作机构

Biogen, Inc.

NCT07019064

/ Recruiting临床1期

A Phase 1, Randomized, Open-label, Single-dose, Crossover, Relative Bioavailability Study of Omaveloxolone Intact Capsules Versus Capsule Contents Sprinkled Over Low-fat, Non-Greek Yogurt in Healthy Adult Subjects

In this study, researchers will learn more about how BIIB141, also known as omaveloxolone or SKYCLARYS?, is processed in the body when taken in different ways. This drug has been approved, or made available for doctors to prescribe, for people with Friedrich's Ataxia (FA) who are at least 16 years old. Currently, people with FA can take it either as whole capsules or opening the capsules and sprinkling its contents over applesauce. The main goal of this study is to learn if BIIB141 is processed any differently when taken sprinkled over low-fat, non-Greek yogurt compared to whole capsules. This will help researchers learn if yogurt could be another option for people to take BIIB141 with.
The main questions researchers want to answer in this study are :
? How does the body process BIIB141 when taken as whole capsules compared to being sprinkled over yogurt?
Researchers will also learn more about :
* How many participants have adverse reactions during the study. An adverse reaction is a health problem that may be caused by the study drug.
* If there are any changes in the participants' overall health during the study
This study will be done as follows:
* Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which participants will check into their study research center.
* Participants will stay at the study research center for about 30 days.
* This is a "crossover" study. In this kind of study, all participants receive the same 2 or more study drugs (or ways of taking the drug), but the order in which they receive them depends on the group they are randomly assigned to.
* In Group 1, participants will take a single dose of BIIB141 as a capsule, followed by a break of 14 days. Then, the participants will take a single dose of BIIB141 sprinkled over yogurt.
* In Group 2, participants will take a single dose of BIIB141 sprinkled over yogurt, followed by a break of 14 days. Then, the participants will take a single dose of BIIB141 as a capsule.
* Each participant will be in the study for up to 57 days.

开始日期2025-06-11

申办/合作机构

Biogen, Inc.

100 项与 Omaveloxolone 相关的临床结果

登录后查看更多信息

100 项与 Omaveloxolone 相关的转化医学

登录后查看更多信息

100 项与 Omaveloxolone 相关的专利（医药）

登录后查看更多信息

134

项与 Omaveloxolone 相关的文献（医药）

2025-12-01·INFLAMMATION RESEARCH

KIAA1429 Silencing ameliorates osteosarcoma progression through promoting ferroptosis via Nrf2/NQO1 axis

Article

作者: Xie, Cheng ; Yang, Lubing ; Xiao, Yihui ; Luo, Jiaquan

BACKGROUND:

Osteosarcoma (OS) is the most common primary malignant bone tumor. Recent insights into ferroptosis have opened new avenues for OS therapy. However, the role of KIAA1429 in regulating ferroptosis and its underlying mechanisms in OS remain unclear.

METHODS:

The effects of KIAA1429 silencing on ferroptosis were evaluated in OS cells treated with erastin alone or in combination with ferrostatin-1 (Fer-1), as well as in an OS mouse model administered sulfasalazine (SAS). Methylation sites on the Nrf2 and NQO1 transcripts were predicted using the SRAMP database and subsequently validated by MeRIP-qPCR. Furthermore, RTA-408 was employed to further investigate the impact of KIAA1429 knockdown on the Nrf2/NQO1 signaling pathway in OS cells.

RESULTS:

KIAA1429 silencing reduced cell viability and increased the expression of ferroptosis-related markers in erastin-treated OS cells, and these effects were reversed by Fer-1. Knockdown of KIAA1429 further enhanced SAS-induced ferroptosis and suppression of xenograft tumor growth. MeRIP-qPCR and dual-luciferase reporter assays demonstrated that KIAA1429 directly regulated Nrf2 via m6A-dependent modification of its 3'UTR. KIAA1429 depletion inhibited viability, migration, and invasion and promoted apoptosis of MG-63 and U2OS cells through suppression of the Nrf2/NQO1 signaling.

CONCLUSION:

KIAA1429 silencing facilitates ferroptosis, thereby delaying OS progression, potentially through modulation of the Nrf2/NQO1 signaling pathway.

2025-10-01·CLINICAL NEUROPHYSIOLOGY

Sensory nerve action potential reappearance after omaveloxolone treatment in patients with Friedreich ataxia

Letter

作者: Leonardis, Lea ; Rotar, Melita

2025-10-01·FREE RADICAL BIOLOGY AND MEDICINE

RTA-408 overcomes cisplatin-resistant lung cancer by inhibiting WWP1-mediated NCOA4 ubiquitination to induce ferritinophagy and ferroptosis

Article

作者: Xu, Ying ; Fei, Yingdan ; Zhang, Sunhan ; Yang, Yueyan ; Zhang, Ting ; Wu, Dongming ; Liu, Teng ; Deng, Shihua ; Wang, Xiaobian ; Chen, Zixin ; Zhu, Ruixiong

Worldwide, pulmonary carcinoma remains the predominant cause of cancer-induced fatalities. Cisplatin (DDP) is a platinum-containing cell cycle-non-specific chemotherapeutic agent and serves as the first-line treatment for non-small cell lung cancer (NSCLC). However, NSCLC cells gradually develop resistance to cisplatin during treatment, reducing drug sensitivity and leading to a significant decrease in the effect of chemotherapy or even treatment failure. The main mechanisms of drug resistance include reduced cellular uptake and apoptotic escape. Strategies to reverse drug resistance often suffer from off-target toxicity or inconsistent efficacy, highlighting the urgent need for new drugs that specifically target resistance pathways. Accordingly, we screened a library of small-molecule compounds associated with ferroptosis. We identified 4-7D (also known as RTA-408), a nuclear factor erythroid 2-related factor 2 activator initially developed to treat Friedreich's ataxia, which has shown potent anti-NSCLC activity in preclinical studies. Its unique ability to regulate both oxidative stress and apoptotic pathways makes it a promising candidate for overcoming cisplatin resistance. Therefore, the present study aimed to determine the key role of omaveloxolone (RTA-408) in overcoming cisplatin-resistant lung cancer. We selected A549/DDP cells as a research model and demonstrated through a series of experimental manipulations that RTA-408 inhibited the growth of A549/DDP cells and inhibited the ubiquitinated degradation of nuclear receptor coactivator 4 through down-regulation of WW structural domain-containing E3 ubiquitin-protein ligase 1 (WWP1), which further induced the development of ferritinophagy and ferroptosis. We report for the first time that RTA-408 overcomes cisplatin-resistant lung cancer by targeting WWP1-mediated ferritinophagy and ferroptosis.

146

项与 Omaveloxolone 相关的新闻（医药）

2025-08-20

·渤健生物

2025年度“医药界诺贝尔奖-盖伦奖”提名揭晓，渤健四款产品入围！

2025年8月11日，美国盖伦基金会（The Galien Foundation）公布2025年度盖伦奖（Prix Galien USA Awards）候选名单。渤健旗下四款创新产品，Qalsody™（凯盛迪™）、Leqembi®（乐意保®）、Skyclarys®及Zurzuvae®入围。盖伦奖被誉为“医药界的诺贝尔奖”，是医药和生物医疗行业的最高荣誉，旨在表彰为改善人类健康做出的杰出科学创新1。盖伦奖的候选药品均为在近5年内获得美国食品药品监督管理局（FDA）批准上市的，并且展现出对改善人类健康产生重大影响的产品。 Qalsody（中文名：凯盛迪™）是全球首款获批上市，用于治疗携带超氧化物歧化酶1（SOD1）基因突变的肌萎缩侧索硬化（ALS）成人患者的疾病修正治疗药物2,3。该产品已于2025年6月在中国商业上市4。 ALS是一种进行性神经退行性疾病，患者大脑和脊髓的上下运动神经元受累，导致肌肉无力、萎缩，最终因吞咽困难、呼吸无力而死亡，患者确诊后的平均寿命为3-5年。ALS的发病原因尚未完全明确，目前已知有多个致病基因被证实与ALS的发病有关。其中，SOD1是首个被发现的ALS致病基因，也是中国ALS人群中最常见的致病基因。SOD1-ALS患者的平均发病年龄约为50岁，患者多为脊髓起病，主要特点为下肢起病，典型表现为上下神经元同时受损5。由于疾病进程不可逆，因此“早发现、早诊断、早治疗”对于延缓疾病进展，维持生活质量至关重要。 Leqembi（中文名：乐意保®）是由渤健和卫材共同开发的，20年来首款被FDA完全批准用于治疗阿尔茨海默病（AD）的疾病修正治疗药物6。该产品已于2024年在中国商业上市7。FDA曾授予其加速审评资格及突破性疗法认定。阿尔茨海默病（AD）是老年人中最常见的神经退行性疾病8，已经成为日益严重的健康危机。全球现存5,000万痴呆患者，其中60-70%是AD源性的痴呆患者9。目前，我国阿尔茨海默病的早期就诊率为28.6%，轻度认知障碍就诊率仅为2.8%。大多数患者确诊时已经是疾病的中晚期，错失了获得早期诊疗的机会。早发现、早诊断、早治疗是最迫切也是最可行的第一步10。 Zurzuvae是FDA批准的，首个用于治疗产后抑郁症（PPD）成人患者的口服疗法11。在此之前，FDA批准的PPD治疗方式仅为静脉注射12。 PPD是一种常见的在女性分娩后出现的精神疾病，其症状可能包括情绪低落、兴趣和愉悦感丧失、睡眠和食欲问题、注意力难以集中、精神运动迟缓或激进、持续的疲劳感、强烈的内疚感以及自我价值感缺失。在极端情况下，患有PDD的产妇甚至可能产生导致自杀的念头或行为13。 *该药品尚未在中国大陆获批上市。 Skyclarys是首款获得FDA批准的，用于治疗16岁以上弗里德赖希共济失调症（Friedreich’sAtaxia，FA）患者的药物14。Skyclarys在2017年6月获得孤儿药认定，并在2021年11月被FDA授予快速通道资格。 FA是一种遗传性的、并会寿命缩短的神经肌肉疾病。大多数患者在青少年时期确诊。患者会出现下肢反射消失，构音障碍，视觉和听觉障碍等症状，并可能在确诊后的10到20年内失去行走能力，平均预期寿命为37岁15。 *该药品尚未在中国大陆获批上市。 Reference： 1. 盖伦奖百度百科：https://baike.baidu.com/item/%E7%9B%96%E4%BC%A6%E5%A5%96/20276181?fr=ge_ala 2. Ionis announced FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS. Retrieved April 25, 2023, from https://ir.ionispharma.com/news-releases/news-release-details/ionis-accounces-fda-advisory-committee-voted-unanimously 3. 托夫生注射液说明书（NMPA批准版本：2024-09-26）[EB/OL]. https://www.biogen.cn/content/dam/corporate/apac/china/zh-cn/disease-areas/als/%E6%89%98%E5%A4%AB%E7%94%9F%E6%B3%A8%E5%B0%84%E6%B6%B2%E8%AF%B4%E6%98%8E%E4%B9%A6_202409.pdf 4. 新华网：《渐冻症精准治疗药物凯盛迪在中国商业上市开启渐冻症“对因治疗”新纪元》https://app.xinhuanet.com/news/article.html?articleId=f1ca049e083c14c989648171694c4099×tamp=1205 5. 王诗婵，商慧芳. 肌萎缩侧索硬化基因型和表型研究进展. Chin J Nerv Ment Dis. 2023:49(5):296-304 6. 湖南日报：《20年来首款获得FDA完全批准的阿尔茨海默病新药上市》https://baijiahao.baidu.com/s?id=1770724150205951078&wfr=spider&for=pc 7. 新浪财经：《中国紧随美国和日本之后，成为第三个"乐意保"上市国家》https://cj.sina.com.cn/articles/view/7243395680/1afbd726002001fzu2 8. https://www-niehs-nih-gov.libproxy1.nus.edu.sg/research/supported/health/neurodegenerative 9. 丁香园：《历时五年余，华山医院郁金泰教授牵头制定阿尔茨海默病循证预防国际指南》 https://neuro.dxy.cn/article/718681 10. 中国新闻网：《专家呼吁：多方聚力共促阿尔茨海默病早诊早治》http://m.chinanews.com/wap/detail/zw/jk/2025/03-31/10392193.shtml 11. FDA Approves First Oral Treatment for Postpartum Depression. Retrieved August 4, 2023 from https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression 12. 中国医药创新促进会：《重磅！口服抗产后抑郁疗法获FDA批准上市》 https://www.phirda.com/artilce_32390.html?module=trackingCodeGenerator 13. 王雅倩，马占强. 产后抑郁症的病理机制与治疗药物. Pharmacy Information 药物资讯, 2025, 14(2), 97-105 14. Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia. Retrieved February 28, 2023, from https://www.businesswire.com/news/home/20230228006450/en/Reata-Pharmaceuticals-Announces-FDA-Approval-of-SKYCLARYS%E2%84%A2-Omavaloxolone-the-First-and-Only-Drug-Indicated-for-Patients-with-Friedreich%E2%80%99s-Ataxia 15. Corben LA, et al., Clinical Management Guidelines Writing Group. Clinical management guidelines for Friedreich ataxia: best practice in rare diseases. Orphanet J Rare Dis. 2022;17(1):415. Biogen-270863-CHN-08/2025

突破性疗法上市批准加速审批

2025-08-20

·Pharmaceutical Technology

PTC’s vatiquinone approval hopes dashed in Friedreich’s Ataxia

The US Food and Drug Administration (FDA) has rejected PTC Therapeutics ’ new drug application (NDA) for vatiquinone in Friedreich’s Ataxia . This follows the biotech’s decision to submit the 15-lipoxygenase (15-LO) inhibitor for approval in the indication, despite it failing to meet its primary endpoint in the Phase III MOVE-FA trial (NCT04577352). PTC Therapeutics’ vatiquinone for Friedrich ataxia has been rejected by the FDA. Image credit: Piotr Swat / ShutterStock.com. Hedging its bets, PTC applied for FDA approval based on statistically significant improvements observed in two subscales of the modified Friedreich Ataxia Rating Scale (mFARS) in the Phase III trial. These related to bulbar and upright stability improvements, which the company claimed were “reflective of key aspects of disease morbidity” in a December 2024 statement. However, the FDA issued PTC with a complete response letter, stating that the application did not provide substantial evidence of vatiquinone’s efficacy, and that “an additional adequate and well-controlled study would be needed to support NDA resubmission”. Despite the FDA’s decision, PTC Therapeutics’ CEO Matthew Klein said: “We believe the data collected to date demonstrate that vatiquinone could provide a safe and effective therapy for both children and adults living with Friedreich’s Ataxia.” GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The company plans to meet with the FDA to discuss potential next steps for the drug in this indication. Friedreich’s Ataxia is a rare, inherited disorder that causes progressive damage to the nervous system. This can cause movement and sensory symptoms, as well as trouble with walking and gait. If the FDA were to be convinced of vatiquinone’s efficacy further down the line, it could become the second drug on the market for Friedreich’s Ataxia – joining Biogen’s Skyclarys (omaveloxolone), which was approved in February 2023 . It could also be the first to be authorised for use in a paediatric population, as Skyclarys is only permitted for use in patients aged 16 years or older. According to GlobalData’s Intelligence Center, Skyclarys made $383m in 2024, with analysts predicting that the drug will become a blockbuster in 2029, raking in $1bn for Biogen. GlobalData is the parent company of Pharmaceutical Technology . PTC’s rare disease woes persist Vatiquinone’s FDA rejection is the most recent event in a swathe of disappointing turnouts for the company, as the conditional approval for its nonsense mutation Duchenne muscular dystrophy (DMD) drug Translarna (ataluren) was pulled by the European Medicines Agency (EMA) in January 2024. This follows a back-and-forth between the two between 2023 and 2024, with the regulator’s committee doubling down on its negative stance after PTC submitted further documentation to the EMA, stating that it “could not draw conclusions on the benefits of Translana” from the new data provided. The EMA also cited “differences between the registries and biases making study comparisons inconclusive” as a key reason for the drug’s recent rejection. PTC has had even less luck in its attempts to get Translarna approved in the US, having faced rejections in 2016 and 2017. The first was related to the insufficient completion of the new drug application (NDA) while the FDA cited a lack of clinical evidence as the primary reason for the second application’s rejection. The company has now filed for approval for the third time in the US, with the FDA accepting its application in October 2024. An action date has not yet been provided by the agency. The drug remains available in the UK through the Medicines and Healthcare products Regulatory Agency (MHRA). Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

临床3期申请上市上市批准

2025-08-01

·抗体圈

渤健 Leqembi 推广现转机，CEO 着眼早期管线储备

摘要：渤健首席执行官克里斯・维赫巴赫在第二季度财报电话会议上表示，与卫材在阿尔茨海默病药物 Leqembi 推广上的合作良好，此前双方不和传言被夸大。本季度 Leqembi 销售额攀升，全球达 1.6 亿美元，美国市场增长 20% 至 6300 万美元。同时，维赫巴赫透露公司将重点关注早期研发项目，通过合作和收购充实管线，为长期发展奠定基础。一、Leqembi 销售增长，市场份额稳固渤健与合作伙伴卫材在阿尔茨海默病药物 Leqembi 的推广上，努力开始收获成果。根据渤健周四发布的第二季度财报，Leqembi 全球销售额达到 1.6 亿美元，其中美国市场销售额增长 20%，达 6300 万美元。这一数据让分析师感到惊喜，尽管他们仍保持谨慎态度。本季度渤健营收增长 7%，达到 26 亿美元。Leqembi 在市场上虽面临礼来 Kisunla 的竞争压力，但据北美业务总裁兼负责人阿丽莎・阿拉伊莫在财报电话会议上称，Leqembi 仍占据 70% 的市场份额。此前，由于医生需适应诊断测试要求及其他挑战，该药物市场推广速度缓慢。不过，阿拉伊莫指出，随着更快、更便捷的生物标志物检测获得批准，生物标志物检测显著增加，更多患者得以诊断并进入治疗流程。她表示：“这远超我们在此时点的预期，我们相信这是一个关键时刻。”首席执行官克里斯・维赫巴赫也提到，基于血液的生物标志物检测有助于 “消除系统中的一些瓶颈”。二、合作关系稳固，回应不和传言渤健与卫材在阿尔茨海默病领域的合作已持续十年。针对因渤健就欧洲商业分配问题提起仲裁，而引发的双方合作关系恶化传言，维赫巴赫在电话会议上进行了回应。他承认多年来双方存在分歧，但强调目前合作关系 “比以往任何时候都要好”。自 2014 年起，双方就联合开发和商业化阿尔茨海默病治疗药物展开合作，卫材主导 Leqembi 全球研发和监管申报，双方共同商业化和推广该产品，且卫材拥有最终决策权。这种合作模式在过去十年中不断磨合，尽管面临挑战，但目前看来仍在稳步推进。三、着眼早期研发，充实管线布局维赫巴赫在电话会议上一如既往地谈到了渤健的业务发展努力。他明确表示：“早期研发项目绝对在计划之中。” 未来，公司将达成更多类似与 City Therapeutics 的研究合作。今年 5 月，渤健与 City Therapeutics 达成合作，支付 4600 万美元预付款，里程碑付款最高可达 10 亿美元，用于开发中枢神经系统疾病的新型 RNAi 疗法。维赫巴赫将早期项目搜寻比作以 18 亿美元收购 Hi - Bio 的行动。他解释称，收购 Hi - Bio 后，渤健在整合的同时保留其完整性，这使得该生物技术公司能够在渤健全球临床试验网络的支持下发挥其专长。他补充道：“这就是我们希望在早期阶段所做的事情。” 通过此类合作与收购，渤健旨在充实早期研发管线，为公司未来发展注入新动力，尤其是在竞争激烈的神经科学领域。四、全年营收预期调整，发展前景可期尽管 Leqembi 销售表现良好，但渤健预计下半年营收增长将放缓。基于此，公司上调了全年业绩指引，预计全年营收将保持平稳增长，营收指引从之前的 145 - 155 亿美元上调至 155 - 160 亿美元。这一调整反映了公司对当前业务状况的评估以及对未来发展的信心。在多发性硬化症（MS）业务方面，由于 Tecfidera 在全球面临仿制药竞争，Tysabri 在欧洲遭遇生物类似药竞争，MS 业务营收下降 4%，至 11 亿美元。不过，罕见病药物业务，如遗传性疾病药物 Skyclarys，营收增长近 2%，达 5.43 亿美元，在一定程度上抵消了 MS 业务的下滑。随着 Leqembi 市场份额的巩固和早期研发管线的逐步充实，渤健在神经科学领域有望迎来新的发展阶段。未来，公司如何平衡现有产品推广与早期研发投入，将持续受到行业和投资者的关注。但就目前而言，Leqembi 销售增长带来的积极信号，以及在早期研发布局上的明确规划，为渤健的未来发展奠定了较为坚实的基础。参考来源：https://www.biospace.com/business/biogens-leqembi-push-getting-easier-as-ceo-eyes-early-stage-pipeline-restock识别微信二维码，添加抗体圈小编，符合条件者即可加入抗体圈微信群！请注明：姓名+研究方向！本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

并购财报临床2期

100 项与 Omaveloxolone 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10964	Omaveloxolone	-	DB12513

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
Friedreich共济失调	美国	Biogen U.S. Corp.	2023-02-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
线粒体肌病	临床2期	美国	Biogen, Inc.	2015-05-05
线粒体肌病	临床2期	丹麦	Biogen, Inc.	2015-05-05
转移性黑色素瘤	临床2期	美国	Biogen, Inc.	2014-10-31
不可切除的黑色素瘤	临床2期	美国	Biogen, Inc.	2014-10-31
乳腺癌	临床2期	美国	Biogen, Inc.	2014-06-30
放射性皮炎	临床2期	美国	Biogen, Inc.	2014-06-30
白内障	临床2期	美国	Biogen, Inc.	2014-05-31
角膜内皮细胞损失	临床2期	美国	Biogen, Inc.	2014-05-31
核性白内障	临床2期	美国	Biogen, Inc.	2014-05-31
眼科外科手术	临床2期	美国	Biogen, Inc.	2014-05-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MDA2024	临床1期	-	32	Omaveloxolone Intact Capsules	餘構廠窪衊繭壓憲鏇膚(夢鹽鏇糧鏇繭繭衊網願) = 構膚蓋繭醖遞顧遞繭蓋繭鏇製獵顧鏇鹽觸觸繭 (齋遞鑰艱壓鹽遞夢願膚, 17.2) 更多	积极	2024-03-03
				Omaveloxolone Sprinkled on Applesauce	餘構廠窪衊繭壓憲鏇膚(夢鹽鏇糧鏇繭繭衊網願) = 壓顧鹹餘鬱襯窪遞範築繭鏇製獵顧鏇鹽觸觸繭 (齋遞鑰艱壓鹽遞夢願膚, 19.7) 更多
NCT02128113 (CTgov)	临床2期	白内障 \| 眼睛疼痛 \| 角膜内皮细胞损失 ... 更多	307	Vehicle Ophthalmic Solution (Vehicle Ophthalmic Solution)	繭網範壓獵構鑰構衊遞(範顧鹽壓鹽鹹鹽選夢構) = 遞積獵簾顧鹹醖觸廠齋製築膚顧窪網憲觸餘築 (鹽鹽築餘觸鹹壓壓範壓, 340.58) 更多	-	2023-05-26
				Omaveloxolone Ophthalmic Suspension 0.5% (Omaveloxolone Opthalmic Suspension 0.5%)	繭網範壓獵構鑰構衊遞(範顧鹽壓鹽鹹鹽選夢構) = 簾網簾顧餘繭築築襯選製築膚顧窪網憲觸餘築 (鹽鹽築餘觸鹹壓壓範壓, 237.00) 更多
NCT02142959 (CTgov)	临床2期	乳腺癌 \| 放射性皮炎	187	3D conformal radiation therapy+Omaveloxolone Lotion 0.5% (Omaveloxolone (RTA 408) Lotion 0.5%)	廠築遞醖製繭窪顧膚範(蓋範築鑰齋遞獵範顧廠) = 遞壓鬱鹹艱構糧網糧繭淵網蓋積蓋淵簾醖醖遞 (齋膚鑰夢選鹹觸糧簾選, 襯餘壓鏇鬱膚艱構壓糧 ~ 顧衊壓鏇憲選淵願鏇膚) 更多	-	2023-05-06
				3D conformal radiation therapy+Omaveloxolone Lotion 3% (Omaveloxolone (RTA 408) Lotion 3%)	廠築遞醖製繭窪顧膚範(蓋範築鑰齋遞獵範顧廠) = 遞觸遞衊齋鑰餘範鹹齋淵網蓋積蓋淵簾醖醖遞 (齋膚鑰夢選鹹觸糧簾選, 齋顧積醖餘築衊夢艱繭 ~ 選鏇範獵網製窪網齋繭) 更多
NCT02255435 (MOXIe, MDA2023) 人工标引	临床2期	Friedreich共济失调	103	Omaveloxolone 150 mg	鹹選壓壓齋積窪鑰糧餘(衊淵餘構遞選網鹽壓獵) = 蓋築遞膚糧艱襯選膚鬱願觸糧壓壓醖繭網鑰鏇 (齋鹽簾淵選窪觸窪遞壓 ) 更多	积极	2023-03-19
				Placebo	鹹選壓壓齋積窪鑰糧餘(衊淵餘構遞選網鹽壓獵) = 窪衊願簾簾鹹鏇鹹鬱選願觸糧壓壓醖繭網鑰鏇 (齋鹽簾淵選窪觸窪遞壓 ) 更多
NCT02255435 (MOXIe, MDA2023) 人工标引	临床2期	Friedreich共济失调	103	Omaveloxolone 150 mg	夢繭選襯艱膚築積鏇鏇(製鏇襯廠築願齋膚淵襯) = 廠衊遞衊築簾選壓築膚鏇願襯齋構積醖淵憲齋 (憲壓網製願襯網鑰網廠 ) 更多	积极	2023-03-19
				Placebo	夢繭選襯艱膚築積鏇鏇(製鏇襯廠築願齋膚淵襯) = 網鹹網餘膚顧範齋鹹襯鏇願襯齋構積醖淵憲齋 (憲壓網製願襯網鑰網廠 ) 更多
NCT02255435 (MOXIe, MDA2023)	临床2期	Friedreich共济失调 Nrf2	-	Omaveloxolone	鏇製鬱糧鏇鹽膚齋憲窪(糧憲簾餘蓋製願構簾獵) = 齋繭鏇廠襯築網膚願襯壓範範淵廠鹹鏇夢襯網 (鹹遞顧襯蓋廠願糧網鹹, 1.09) 更多	积极	2023-03-19
				Placebo	鏇製鬱糧鏇鹽膚齋憲窪(糧憲簾餘蓋製願構簾獵) = 壓憲選壓製衊憲顧廠衊壓範範淵廠鹹鏇夢襯網 (鹹遞顧襯蓋廠願糧網鹹, 1.44) 更多
NCT02255435 (FDA) 人工标引	临床2期	Friedreich共济失调	103	SKYCLARYS 150 mg	顧餘鹽壓齋壓艱遞鏇艱(衊簾醖鏇憲醖願蓋鹽壓) = 衊襯鑰壓顧選夢鏇構鹹蓋構範製鏇鏇廠鏇積選 (鹽顧壓簾廠廠蓋壓壓襯 )	积极	2023-02-28
				placebo	顧餘鹽壓齋壓艱遞鏇艱(衊簾醖鏇憲醖願蓋鹽壓) = 餘製簾齋餘糧簾鏇顧壓蓋構範製鏇鏇廠鏇積選 (鹽顧壓簾廠廠蓋壓壓襯 )
NCT02255435 (MOXIe, Corporate Publications) 人工标引	临床2期	Friedreich共济失调	-	Omaveloxolone	範觸夢顧淵遞壓構艱製(積齋壓簾襯選壓廠衊膚): difference = -2.17±1.09 更多	积极	2022-08-08
				Placebo
NCT02255435 (MOXIe, MDA2022)	临床2期	Friedreich共济失调 Nrf2	-	Omaveloxolone	膚衊膚築壓鏇簾積窪襯(願醖鹹顧窪窪獵觸淵膚) = 窪廠糧鹹餘範顧簾構鏇網鑰積構範鑰壓築鏇壓 (積衊遞獵遞鬱構襯餘夢, 1.45) 更多	积极	2022-03-13
				Placebo	膚衊膚築壓鏇簾積窪襯(願醖鹹顧窪窪獵觸淵膚) = 簾鹽遞鏇襯製糧獵憲繭網鑰積構範鑰壓築鏇壓 (積衊遞獵遞鬱構襯餘夢, 1.07) 更多
NCT02259231 (CTgov)	临床1/2期	转移性黑色素瘤 \| 不可切除的黑色素瘤	41	Ipilimumab (3 mg/kg)+Omaveloxolone Capsules (2.5 mg/capsule) (Omaveloxolone 5 mg & Ipilimumab)	鏇繭製鏇廠憲衊齋構鬱 = 衊齋顧夢積願膚齋憲窪繭夢遞願夢構齋築遞顧 (憲襯獵醖膚選範壓簾顧, 憲鏇憲鑰鏇壓淵齋觸鹹 ~ 憲範鑰願築醖簾夢網壓) 更多	-	2021-06-24
				Ipilimumab (3 mg/kg)+Omaveloxolone Capsules (10 mg/capsule) (Omaveloxolone 10 mg & Ipilimumab)	鏇繭製鏇廠憲衊齋構鬱 = 製獵齋膚遞遞積範齋淵繭夢遞願夢構齋築遞顧 (憲襯獵醖膚選範壓簾顧, 顧鹹齋繭艱襯積鏇鑰淵 ~ 壓膚鑰夢鑰獵製餘鏇齋) 更多